Advancing a multi-asset pipeline of high-impact therapeutic solutions

Our pipeline is comprised of innovative therapeutic product candidates we believe have the potential for value creation using our partnership-enabled business model.
Target Disease
Program
Target Population
Preclinical Clinical Feasibility Clinical Pivotal
Hypertensive Heart Disease
$17 Billion Annual Global Opportunity
Atrioventricular Interval Modulation(AVIM) Therapy
Preclinical Clinical Feasibility Clinical Pivotal
Hypertension (HTN) & Pacemaker
BACKBEAT Global Pivotal Study Enrolling & FDA Breakthrough
HTN with Increased CV Risk
(Non-pacemaker indicated)
FDA Breakthrough
HTN & Heart Failure
FDA Breakthrough
AVIM/Cardiac Neuromodulation Therapy may have additional clinical application in advanced heart failure.
Atherosclerotic Artery Disease
$10 Billion Annual Global Opportunity
Virtue® Sirolimus AngioInfusion™ Balloon (SAB)
Preclinical Clinical Feasibility Clinical Pivotal
Coronary In-Stent Restenosis (ISR)
IDE Approved & FDA Breakthough
Coronary Small Vessel (SV)
FDA Breakthough
Below-the-Knee (BTK)
FDA Breakthough
Other Coronary & Peripheral Indications
SirolimusEFR™ may have potential clinical application in a variety of non-vascular indications.

Our flagship product candidates, AVIM Therapy and Virtue SAB, exemplify key criteria that characterize innovations optimized for strategic partnerships:
Target mature therapeutic device markets with significant unmet needs
Provide high-impact procedure-based solutions with rapid adoption potential
Offer strategic and financial benefits to a commercial partner and Orchestra BioMed

* Plan to leverage existing coronary in-stent restenosis (ISR) data to support potential Pivotal Study; Virtue SAB has received Breakthrough Device Designation for:

  1. The balloon dilation of the stenotic portion (up to 26 mm in length) of a stented coronary artery that is 2.25 to 4.0 mm in diameter, for the purpose of improving lumen diameter.
  2. The balloon dilation of the de novo stenotic portion (up to 28 mm in lesion length) of a native coronary artery of 2.0 mm to 2.5 mm in diameter (small coronary arteries), for the purpose of improving lumen diameter.
  3. The balloon dilation of the stenotic portion (up to 18 mm in length) of an infrapopliteal artery (P-3 segment or distal, below the knee) with a reference vessel diameter (RVD) of 2.25 to 4.0 mm, for the purpose of improving lumen diameter.

Virtue® SAB is investigational and not commercially approved.

AVIM therapy is investigational and not commercially approved.